1 completed, 1 recruiting, 1 terminated. 2 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow 68Ga-DOTA-TOC: new trials by email Literature Review of 68Ga-DOTA-TOC trials Research Report on 68Ga-DOTA-TOC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) 61Cu-NODAGA-LM3, Comparator - Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 27 | 2025-02-05 | 2025-05-30 |
| Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor 90Y-DOTA-TOC, 68Ga-DOTA-TOC - Neuroendocrine Tumor | Early Phase 1 | Completed | Thomas Hope | 10 | 2017-07-01 | 2020-07-07 |
| 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography - Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm | Early Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2017-05-16 | 2021-02-15 |
Neuroendocrine Tumors (3) · Meningioma (1) · Multiple Endocrine Neoplasia Type 1 (1) · von Hippel-Lindau Disease (1)
M.D. Anderson Cancer Center (1) · Thomas Hope (1) · University Hospital, Basel, Switzerland (1)
United States (2) · Switzerland (1)
Guillaume Nicolas, Dr. (1) · Homer A Macapinlac, MD (1) · Thomas Hope, MD (1)
2023 (1)